Sources

12 Total Sources

Daraxonrasib Doubles Survival in Phase 3 Pancreatic Cancer Trial

Daraxonrasib Doubles Pancreatic Cancer Survival in Phase 3 Trial

What is Daraxonrasib? Ben Sasse hails "miracle drug" on shrinking tumors - Newsweek

The Times7d ago

Daily pill could revolutionise cancer treatment

binaytara.org1d ago

Daraxonrasib and the RASolute 302 Trial: A Paradigm Shift in the RAS Targeting Era and Management of Pancreatic Cancer | Cancer News

audiomedica.com7d ago

Eileen M O’Reilly MD; ASCO 2026: RAS G12 Targeting Drug Daraxonrasib Doubles Survival with Pancreas Cancer in Phase 3 RASolute 302 Study

Stanford Medical Center Report7d ago

A pancreatic cancer drug provides new hope: Five things to know about daraxonrasib

Pancreatic cancer patient sees 86% decrease in CA 19-9 levels with daraxonrasib treatment and lifestyle changes

Instagram7d ago

The new treatment, Daraxonrasib, not only has the potential to extend survival but may also improve patients' quality of life. It's awaiting FDA approval. Click Watch Live at the link in our bio for ...

Zacks Investment Research7d ago

RVMD Starts Treatment in Phase III Pancreatic Cancer Study on Zoldonrasib - June 24, 2026 - Zacks.com

Women's Health7d ago

A New Medication May Double the Survival Time for Pancreatic Cancer Patients

조선비즈7d ago

Revolution drug doubles pancreatic cancer survival, ignites Korea-led race - CHOSUNBIZ

WRIC ABC 8News7d ago

Doctors say new pancreatic cancer drug is giving hope to advanced stage patients | WRIC ABC 8News